Abstracts Archive - Page 238 of 2607 - ACR Meeting Abstracts

Abstract Number: 2460 • ACR Convergence 2024
Severe Gastrointestinal Involvement in Systemic Sclerosis: A New “Transversal” Subset of Disease to Be Prioritised for Intervention Trials
Marco Minerba¹, Riccardo Bixio², Seda Colak³, Stefano Di Donato⁴, Lesley-Anne Bissell⁵ and Francesco Del Galdo⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²University of Verona, Verona, Verona, Italy, ³Gulhane Training and Research Hospital, Ankara, Turkey, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Gastrointestinal (GI) involvement is the most frequent internal complication of systemic sclerosis (SSc) and, when severe, it has a major influence on patient function.…
Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 0403 • ACR Convergence 2024
Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
Melissa Oliver¹, susan Thornhill², Beverley Shea³, Jonathan Akikusa², Christian Hedrich⁴, Philip Mease⁵ and Yongdong (Dan) Zhao⁶, and OMERACT CNO & SAPHO Working Group, ¹Indiana University, Indianapolis, IN, ²Royal Children's Hospital, Parkville, Victoria, Australia, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶University of Washington, Redmond, WA
Background/Purpose: Disease outcome measures for chronic nonbacterial osteomyelitis (CNO) & Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) have been proposed and reported but have lacked…
Abstract Number: 0407 • ACR Convergence 2024
Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India
Lekshmi Minikumari Rahulan¹, Able Lawrence² and Amita Aggarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Familial aggregation of autoimmune disease as well as co-occurrence of multiple autoimmune diseases in one individual is known and it suggests a shared genetic…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 0408 • ACR Convergence 2024
Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Michael Matt¹, Mariana Correia Marques², Sabrina Fuehner³, Lexi Auld¹, George Tomlinson⁴, Michael Ombrello⁵, Yukiko Kimura⁶, Christoph Kessel⁷ and grant schulert¹, and the CARRA FROST Investigators, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²National Institutes of Health, Bethesda, MD, ³Universitaetsklinikum Muenster, Muenster, Germany, ⁴University of Toronto, Toronto, ON, Canada, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Hackensack Meridian School of Medicine, New York, NY, ⁷University Hospital Muenster, Muenster, Germany
Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…
Abstract Number: 0392 • ACR Convergence 2024
Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Geoffrey Thiele¹, Panteha Hayati Rezvan², Michal Cidon², Carlos Hunter³, Michael Duryee³, Ted Mikuls³ and Geoffrey Thiele³, ¹Children's Hospital of Los Angeles, Omaha, NE, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Insa Mannstadt¹, J. Alex B. Gibbons² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
Abstract Number: 0399 • ACR Convergence 2024
Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort
Rachel Dickey¹, Doel Dhar², Srushti Gangireddy³, Henry H. Ong³, Wei-Qi Wei³ and Anna Patrick³, ¹Lipscomb University College of Pharmacy, Athens, TN, ²Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe disease with symptoms of fevers, rash, and arthritis. High levels of the inflammatory cytokines interlukin-1 (IL-1)…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0420 • ACR Convergence 2024
Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases
Sarah Lieber¹, Lucy Masto¹, Amaya Smole², Ranqing Lan¹, Michael Parides¹, Jonah Levine¹, Bessie Stamm¹, Caroline Siegel¹, Lisa Mandl¹, Michael Lockshin³, Medha Barbhaiya¹ and Lisa Sammaritano⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Brooklyn, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY
Background/Purpose: Although guidelines support acceptability of breastfeeding (BF)/pumping in women with systemic rheumatic diseases (SRDs) when taking BF-compatible medications, little is known about factors influencing…
Abstract Number: 0433 • ACR Convergence 2024
Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
Eleonora Giacobbe¹, Maria Chiara Gerardi², Clizia Gagliardi², Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Milan, Lombardia, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
Abstract Number: 0402 • ACR Convergence 2024
Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts
Mariana Correia Marques¹, Erin Balay-Dustrude², Claudia Bracaglia³, Marinka Twilt⁴, Karen Onel⁵, Simone Appenzeller⁶, Fatma Dedeoglu⁷, Esraa Eloseily⁸, Penelope Martinez Jimenez⁹, Rebecca Trachtman¹⁰, Francesca Minoia¹¹ and Susan Shenoi¹², and on behalf of the MAS/sJIA WP of PReS and CARRA sJIA Workgroup, ¹National Institutes of Health, Bethesda, MD, ²University of Washington, Seattle, WA, ³IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴Alberta Children's Hospital, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada, Calgary, AB, Canada, ⁵HSS, New York, NY, ⁶Department of Orthopedics, Rheumatology and Traumatology. University of Campinas, Campinas, Brazil, ⁷Boston Children's Hospital, Boston, MA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Icahn School of Medicine at Mount Sinai- Elmhurst Hospital Center, Rego Park, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: Multinational research is essential to globally improve the management of systemic juvenile idiopathic arthritis (sJIA), improve recognition of rare complications like lung disease, and…
Abstract Number: 2502 • ACR Convergence 2024
Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
Eduardo Martin Nares, Gabriela Hernández-Molina, Diana Aguilar-León, Norma Ofelia Uribe-Uribe and Janette Furuzawa-Carballeda, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by tissue infiltration with IgG4+ plasma cells. Fibrosis in the target organs is one of…
Abstract Number: 2486 • ACR Convergence 2024
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Shoichi Fukui¹, Naoki Iwamoto¹, Ayaka Umetsu², Momoko Okamoto², Keita Fujikawa², Akinari Mizokami², Takuya Tomokawa³, Kazusato Hara³, Yoshiro Horai³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, ³Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, ⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].